AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

SURGICAL INNOVATIONS GROUP PLC

Remuneration Information Nov 28, 2025

7938_dirs_2025-11-28_ff6a0b82-6570-48af-a23e-f8e7b4a49492.html

Remuneration Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3418J

Surgical Innovations Group PLC

28 November 2025

Surgical Innovations Group plc

("Surgical Innovations", the "Company", or the "Group")

New LTIP & Grant of Options

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces the establishment of a new Long Term Incentive Plan ("2025 LTIP") for certain executive directors and employees in order to incentivise them in a manner that aligns with the interests of the Company's shareholders.

New LTIP

Under the terms of the 2025 LTIP, the Company has awarded nil cost share options (the "Options") over a total of 16,086,955 ordinary shares of 1 pence each in the Company ("Ordinary Shares") including to certain persons discharging managerial responsibilities ("PDMRs") as set out below.

The Options may be exercised at nil cost and are subject to performance criteria relating to revenue growth, EBIT growth and total shareholder returns alongside continuous employment with the Company for a period of three years ending on 26th November 2028.

The following PDMRs have been awarded Options:

PDMRs Role No. of Options awarded Total Options held post award
David Marsh Chief Executive Officer 9,130,434 9,130,434
Brent Greetham Chief Financial Officer 6,956,521 6,956,521

In developing the 2025 LTIP and determining the award of Options, the Remuneration Committee engaged in consultation with the Company's largest shareholder.

For further information please contact:

Surgical Innovations Group plc www sigroupplc com
David Marsh, CEO Tel: 0113 230 7597
Brent Greetham, CFO
Singer Capital Markets (Nominated Adviser & Broker) Tel: 020 7496 3000
Alex Bond / Oliver Platts
Walbrook PR (Financial PR & Investor Relations) Tel: 020 7933 8780 or [email protected]
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / 07584 391 303

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs, the Company's Reposable portfolio enables healthcare providers to reduce both plastic waste and their CO2 footprint as they strive for net zero.

A close-up of a business card Description automatically generated

Further information

Further details of the Group's businesses and products are available on the following websites:

www.sigroupplc.com

www.surginno.com

www.elementalhealthcare.co.uk

To receive regular updates by email, please contact [email protected]

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

1.    David Marsh

2.    Brent Greetham

2

Reason for the notification

a)

Position/status

1.    Chief Executive Officer

2.    Chief Financial Officer

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Surgical Innovations Group plc

b)

LEI

2138004GHGUH3HUZE156

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 1p

GB0004016704

b)

Nature of the transactions

Grant of options

c)

Price(s) and volume(s)

Price(s) Volume(s)
1.               nil

2.               nil
1.               9,130,434

2.               6,956,521

d)

Aggregated information

-     Aggregated volume

-     Price

N/A

N/A

e)

Date of the transaction

27 November 2025

f)

Place of the transaction

Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFZMZMVNNGKZM

Talk to a Data Expert

Have a question? We'll get back to you promptly.